Balchem Corp. 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Balchem Corporation on February 6, 2006, reporting events occurring on February 8, 2006. The filing details the completion of a strategic acquisition and the execution of a new financing agreement to support the transaction.
Key Financial Metrics and Transaction Details
- Acquisition Price: $17,350,000 for 100% of Chelated Minerals Corporation (CMC), subject to working capital adjustments.
- Financing Structure:
- Term Loan: $10,000,000 secured from Bank of America, N.A.
- Revolving Facility: $3,000,000 available (undrawn as of filing date).
- Cash Funding: Remaining purchase price funded via Balchem's cash on hand.
- Debt Terms: Term loan matures March 1, 2009, with monthly principal and interest payments. Interest rate is LIBOR plus 100 basis points.
- Guarantors: Balchem Minerals Corporation and BCP Ingredients, Inc. guarantee the loan obligations.
Material Changes
Balchem completed the acquisition of Chelated Minerals Corporation (CMC), a privately held Utah corporation specializing in nutrient delivery technology for the animal health industry. This transaction expands Balchem's Animal Nutrition and Health product line. Concurrently, the company entered into a material definitive agreement with Bank of America to secure the $10 million term loan and $3 million revolving credit facility.
Outlook, Risks, and Contingencies
The acquisition is intended to complement existing product lines through CMC's proprietary chelation process. The filing notes that required financial statements of the acquired business and pro forma financial information will be filed by amendment within 71 days of the report date. No specific risks or contingencies regarding the integration or performance of CMC are detailed in this specific text, other than the standard purchase price adjustment clause based on actual working capital.
Investor Verification Checklist
- Verify the final purchase price after working capital adjustments are calculated.
- Review the upcoming pro forma financial information to assess the impact of the $10 million debt on leverage ratios.
- Confirm the integration timeline and expected synergies between Balchem and CMC's animal health technologies.
- Monitor the utilization of the $3 million revolving credit facility in future quarters.